BridgeBio to Present Cardiovascular Mortality Data for Acoramidis at ESC Congress 2025
核心洞察
BridgeBio will present 42-month open-label extension data showing acoramidis reduces cardiovascular mortality in ATTR-CM (搜索) patients at ESC Congress 2025.
Additional presentations will demonstrate acoramidis-mediated improvements in NT-proBNP levels and NAC ATTR staging at 30 months compared to placebo.
Attruby (acoramidis) is approved as a transthyretin (搜索) stabilizer for treating ATTR-CM (搜索) cardiomyopathy (搜索) to reduce cardiovascular death and hospitalizations.
BridgeBio Pharma announced it will present extended clinical data for its transthyretin (搜索) stabilizer acoramidis (Attruby) at the European Society of Cardiology Congress 2025 in Madrid, Spain, from August 29 to September 1, 2025. The presentations will include pivotal cardiovascular mortality data from the ATTRibute-CM open-label extension study at 42 months.
Key Clinical Presentations
The primary oral presentation, titled "Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study," will be delivered by Dr. Kevin Alexander from Stanford University School of Medicine on Saturday, August 30 at 1:15 pm CEST. This represents the longest follow-up data available for acoramidis in treating transthyretin-mediated amyloidosis (搜索) cardiomyopathy (搜索) (ATTR-CM (搜索)).
Two additional electronic poster presentations will showcase 30-month data from the ATTRibute-CM study. Dr. Nitasha Sarswat from UChicago Medicine will present data on acoramidis-mediated improvement in NT-proBNP levels compared with placebo on Sunday, August 31. Dr. Julian Gillmore from University College London's Centre for Amyloidosis will present findings on beneficial effects on NAC ATTR staging changes from baseline on Saturday, August 29.
Drug Profile and Safety
Attruby (acoramidis) is indicated for treating cardiomyopathy (搜索) of wild-type or variant transthyretin-mediated amyloidosis (搜索) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. The drug functions as a transthyretin (搜索) stabilizer, addressing the underlying mechanism of ATTR-CM (搜索).
Safety data from clinical trials show diarrhea occurred in 11.6% of acoramidis-treated patients versus 7.6% on placebo, while upper abdominal pain was reported in 5.5% versus 1.4% respectively. The majority of adverse reactions were mild and resolved without requiring drug discontinuation. Discontinuation rates due to adverse events were comparable between acoramidis and placebo groups at 9.3% and 8.5% respectively.
Company Background
BridgeBio Pharma, founded in 2015, focuses on developing transformative medicines for genetic diseases. The company's development pipeline spans from early-stage science to advanced clinical trials, with acoramidis representing a key asset in their portfolio targeting rare genetic conditions.